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Juha Koskenvuo2,4, Juhani Knuuti1 and Olli Arjamaa5Abstract
Background: As it remains unclear whether hypoxia of cardiomyocytes could trigger the release of brain natriuretic
peptide (BNP) in humans, we investigated whether breathing normobaric hypoxic gas mixture increases the
circulating NT-proBNP in healthy male subjects.
Methods: Ten healthy young men (age 29 ± 5 yrs, BMI 24.7 ± 2.8 kg/m2) breathed normobaric hypoxic gas mixture
(11% O2/89% N2) for one hour. Venous blood samples were obtained immediately before, during, and 2 and
24 hours after hypoxic exposure. Cardiac function and flow velocity profile in the middle left anterior descending
coronary artery (LAD) were measured by Doppler echocardiography.
Results: Arterial oxygen saturation decreased steadily from baseline value of 99 ± 1% after the initiation hypoxia
challenge and reached steady-state level of 73 ± 6% within 20–30 minutes. Cardiac output increased from 6.0 ± 1.2
to 8.1 ± 1.6 L/min and ejection fraction from 67 ± 4% to 75 ± 6% (both p < 0.001). Peak diastolic flow velocity in the
LAD increased from 0.16 ± 0.04 to 0.28 ± 0.07 m/s, while its diameter remained unchanged. In the whole study
group, NT-proBNP was similar to baseline (60 ± 32 pmol/ml) at all time points. However, at 24 h, concentration of
NT-proBNP was higher (34 ± 18%) in five subjects and lower (17 ± 17%), p = 0.002 between the groups) in five
subjects than at baseline.
Conclusion: In conclusion, there is no consistent increase in circulating NT-proBNP in response to breathing
severely hypoxic normobaric gas mixture in healthy humans, a possible reason being that the oxygen flux to
cardiac myocytes does not decrease because of increased coronary blood flow. However, the divergent individual
responses as well as responses in different cardiac diseases warrant further investigations.
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Natriuretic peptides are endogenous peptide hormones de-
rived from the myocardium. They have autoregulatory ef-
fects to the heart by preventing atrial stretch via regulation
of sodium and water balance but they also regulate directly
blood vessel tonus and whole body energy homeostasis [1].
Especially brain natriuretic peptide (BNP), which possesses* Correspondence: ilkka.heinonen@utu.fi
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unless otherwise stated.significant cardioprotective properties, is also frequently
measured in patients with cardiovascular diseases as it pro-
vides diagnostic and prognostic value in many clinical sce-
narios. BNP is generally regarded to be released from the
ventricles of the heart in response to volume or pressure
overload. Emerging evidence from cell culture studies and
animal experiments, however, suggests that also hypoxia [2]
of cardiomyocytes could trigger the release of BNP [3,4]. It
has also been shown with cultured human myocardial cells
that hypoxia can induce BNP release [5]. Hypoxia effect
can be separated from cardiomyocyte stretch [6], although
not all human cell culture studies have repeated this re-
sponse [7].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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findings remains unclear, however, as tissue oxygen levels
may never reach such low and long-standing severe hyp-
oxia values as is generally used in vitro studies. Neverthe-
less, normobaric hypoxic exposure for 60 minutes has been
shown to induce slight increase in N-terminal BNP, but this
study was performed in highly selected group of subjects
that showed either high or low renin-angiotensin system
activity [8]. On the other hand, a very severe (correspond-
ing to altitude of 9144 m), but short (1–3 min) exposure to
hypobaric hypoxia did not cause an increase in BNP levels
[9]. Similarly, also a short hypobaric chamber exposure
(25 min) at rest followed by 1 min of exercise did not lead
to immediate increase in circulating BNP in healthy
humans [10].
However, it might be that as BNP peptide is stored
only in small amounts in secretary granules of ventricu-
lar myocytes [11], increase in BNP becomes apparent
only after sufficient time period following hypoxia ex-
posure, when gene expression has been triggered by
hypoxia to form more of the peptide. Furthermore, car-
diac function and coronary blood flow responses have
not been monitored simultaneously with hypoxic expos-
ure in these previous human studies, making it difficult
to evaluate whether loading conditions for instance are
affected and contribute to hypoxia-induced BNP release.
Consequently, to elucidate these yet remaining aspects
of the possible hypoxia-induced BNP release in humans
in vivo, we measured circulating N-terminal proBNP
levels repeatedly during breathing severely hypoxic gas
mixture, and 2 hours and 24 hours after the exposure.
Furthermore, cardiac function was also assessed com-
prehensively and simultaneously during hypoxic expos-
ure, to further understand the possible independent role
of hypoxia to trigger BNP release from cardiomyocytes.Methods
Subjects
Ten healthy Caucasian young men (age 29 ± 5 yrs, height
181 ± 4 cm, weight 81 ± 11 kg, BMI 24.7 ± 2.8 kg/m2)
volunteered to participate in this study. The purpose, na-
ture, and potential risks of the study were explained to the
subjects before they gave their written informed consent
to participate. The subjects were normotensive non-
smokers with no history of hypercholesterolemia, not tak-
ing any medications and had never experienced angina
symptoms. The normal health status of the subjects was
confirmed by a medical doctor by clinical examination,
ECG and cardiac echocardiography before the experi-
ments. The study was performed according to the Declar-
ation of Helsinki and was approved by the Ethics
Committee of the Hospital District of South-West
Finland.Hypoxic exposure and blood sampling
The subjects were requested to avoid strenuous physical ex-
ercise in the 48 h prior to the experiments. The hypoxic ex-
posure was performed in a fasting state and always started
around 9 AM with study preparations. In these prepara-
tions 12-lead ECG was positioned and an antecubital vein
was cannulated for blood sampling. Venous blood samples
were obtained before, and 2 and 24 hours after hypoxic ex-
posure and analyzed by standard hospital practices. After
initial preparations, subjects breathed normobaric hypoxic
gas mixture (11% O2/89% N2) for one hour. Arterial oxygen
saturation was continuously measured by pulse oximetry
and valid plethysmogram signal was confirmed throughout
the studies. All of these measurements were performed
when subjects were resting supine.
Analysis of BNP
Plasma samples (0.9 ml) were first concentrated by extrac-
tion with SepPak C18 cartidges, to enable the quantification
of the very low levels of circulating BNP peptides in healthy
young subjects. NT-proBNP concentrations were deter-
mined by immunoassay specific to human NT-proBNP10–
29 as previously reported [12,13]. NT-proBNP is a product
of the same precursor and therefore reflects the secretion
of the biologically active peptide BNP.
Echocardiography
Transthoracic 2 dimensional (2D) and Doppler echocardio-
graphic studies were performed with Acuson Sequoia 512
(Siemens Medical Solutions, USA) equipped with 3V2c
transducer at rest and 20 min after beginning of the
hypoxia. The digitized images were stored in Syngo
Dynamics-system (Siemens, Siemens Medical Solutions,
USA) for later analysis. The study subjects were examined
in a left lateral decubitus position. Left and right ventricular
dimensions and left ventricular wall thickness and ejection
fraction and left atrial dimension were measured in
parasternal long axis view from 2-dimensionally guided M-
mode tracings using second harmonic 4.25 MHz scanning
frequency. Pulmonary artery flow velocity (pulsed wave
Doppler) was measured in the parasternal short axis view
at the level of aortic root. The mitral inflow velocities and
blood flow velocities in pulmonary veins (pulsed wave Dop-
pler), pressure gradient between right ventricle and right
atria (continuous wave Doppler), tissue Doppler velocities
of the mitral annulus and M-mode traced valvular ring am-
plitudes were all recorded from apical 4-Chamber view.
Vena cava inferior was examined from the subcostal view.
The mean of at least three consecutive cardiac cycles was
always calculated and averaged.
Diameter and blood flow velocity (pulsed wave
Doppler) were measured in the mid left anterior de-
scending coronary artery using a modified parasternal
short axis view focusing on the interventricular sulcus
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[14,15].
Statistical analysis
Statistical analysis was performed using SAS/STAT stat-
istical software (version 9.2, SAS institute Inc., Cary, NC,
USA). Two-tailed Student’s t-test or one-way (or two-
way in terms of group differences) ANOVA for repeated
measurements was used for the analysis of statistical dif-
ferences when appropriate. ANOVA was followed by
Tukey post-hoc test if necessary to detect differences in
different study time points, or groups. P values < 0.05
were considered statistically significant. All data are
shown as mean ± SD.
Results
All of the subjects had normal baseline arterial oxygen sat-
uration of 99 ± 1% at baseline, which decreased steadily
after the initiation of hypoxic breathing and reached a
stable steady-state level (73 ± 6%) within 20–30 min after
the initiation of hypoxic exposure based on continuous40
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Figure 1 Arterial oxygen saturation, as determined by pulse oxymetr
(0 min), repeatedly during 60 min of hypoxic exposure, and 2 hours a
to 0 min and 2 h, #p < 0.05 compared to 60 min.pulse oximetry (Figure 1A). This level of oxygen saturation
was maintained until the removal of the hypoxic mask after
1 hour, after which saturation reached normal, pre-hypoxic
values (99 ± 1%) within 1 min (Figure 1A). Hemoglobin
concentration was increased towards the end of the hypoxic
exposure, but returned to pre-hypoxia levels after 2 hours
of returning to normoxic conditions (Figure 1B).
Heart rate response followed a similar, but reversed
pattern to that of arterial oxygen saturation, being 58 ±
9 bpm at resting baseline, 79 ± 11 during hypoxia, and
61 ± 1 bpm two hours after the end of hypoxic exposure
(Figure 2A). Systolic blood pressure did not change
(Figure 2B) in response to hypoxia (p = 0.42 in ANOVA),
but diastolic blood pressure was slightly lower in the end
of hypoxia than at baseline or during normoxic recovery
from the hypoxia exposure (Figure 2C).
In Table 1 parameters describing cardiac function at
baseline and in hypoxia are presented. No regional wall
motion abnormalities were detected. Of note, hypoxia
led to increased cardiac output and ejection fraction, but
atrial sizes did not change. Left coronary artery blood****
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Figure 2 Heart rate (A), and systolic (B) and diastolic blood pressures (C) before hypoxia (0 min), repeatedly during 60 min of hypoxic
exposure, and 2 hours after the exposure. **p < 0.01, and ***p < 0.001 compared to 0 min and 2 h.
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unchanged in response to hypoxia. A decrease in E/A-
ratio was also observed.
At the whole study group level there was no change in
NT-proBNP concentration in response to applied sys-
temic hypoxia (Figure 3A). However, two distinct NT-
proBNP response groups to hypoxia were also identified,
as in five subjects the 24 h concentration of NT-proBNP
was elevated on average 34 ± 18% as compared with the
baseline concentration, while in five subjects it was re-
duced by an average of 17 ± 17% lower (Figure 3B). NT-
proBNP either increased or decreased in all of these fivesubjects. Mean heart rate was consistently higher
throughout the experiment in the five subjects with ele-
vated BNP at 24 hours (62 ± 11, 77 ± 8, 78 ± 9, 81 ± 10,
84 ± 7, 78 ± 8, 81 ± 6, 65 ± 11 bpm at baseline before
hypoxia, and 5, 10, 20, 30, 45, 60 min time points dur-
ing, and 2 hours after hypoxia, respectively) as compared
to the other five individuals (55 ± 5, 73 ± 6, 74 ± 5, 76 ±
12, 73 ± 9, 73 ± 5, 76 ± 11, 56 ± 6, respectively, p < 0.01
for the group difference in two-way ANOVA, hypox-
ia*group interaction p = NS), but there were no group
differences, or even trends towards differences, in arter-
ial oxygen saturation, haemoglobin concentration, blood
Table 1 Cardiac function at baseline and after 20 minutes
exposure to hypoxic stimulus
Baseline Hypoxia
Cardiac output (L/min) 6.0 ± 1.2 8.1 ± 1.6***
Ejection fraction (%) 67 ± 4 75 ± 6***
RV ED diameter (mm) 25 ± 4 26 ± 3
RA diameter (mm) 20 ± 4 19 ± 2
LA diameter (mm) 39 ± 4 38 ± 3
PA blood flow velocity (m/s) 0.8 ± 0.1 1.0 ± 0.1*
Vena cava inferior (mm) 16.8 ± 4.6 15.2 ± 4.2
RV-to-RA pressure gradient (mmHg) 28 ± 5 31 ± 3*
RV E’/ A’ (cm/s) 1.5 ± 0.4 1.4 ± 0.2
RV Sm (cm/s) 0.20 ± 0.04 0.24 ± 0.04*
Pulmonary vein s/d ratio 1.3 ± 0.2 1.4 ± 0.3
TAPSE (cm) 2.6 ± 0.2 3.0 ± 0.3**
LAD diameter (cm) 5.62 ± 0.64 5.60 ± 0.64
LAD blood flow velocity (m/s) 0.16 ± 0.4 0.28 ± 0.07**
LV lateral wall E’/A’ 1.9 ± 0.7 1.5 ± 0.6
LV septal wall E’/A’ 1.6 ± 0.3 1.5 ± 0.3
LV septum Sm (cm/s) 0.12 ± 0.02 0.15 ± 0.05
LV lateral wall Sm (cm/s) 0.16 ± 0.06 0.19 ± 0.06
Lateral mitral annular displacement (cm) 1.5 ± 0.2 1.8 ± 0.2**
Septal mitral annular displacement (cm) 1.5 ± 0.1 1.7 ± 0.3*
E/A –ratio 1.6 ± 0.3 1.4 ± 0.2*
LV = left ventricle, RV = Right ventricle, LA = left atrium , RA = right atrium,
TAPSE = Tricuspid annular plane systolic excursion, PA = pulmonary artery,
E’ = tissue-Doppler early diastolic velocity, A’ = tissue-Doppler late diastolic
velocity, Sm = tissue-Doppler systolic velocity, E = Mitral inflow early peak
velocity, A = Mitral inflow atrial peak velocity. *p < 0.05, **p < 0.01, ***p < 0.001
compared to baseline. LAD = the left anterior descending coronary artery.
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sured in the present study (data not shown).
Discussion
In the present study we measured cardiac function, cor-
onary blood flow velocity and peripheral circulating
levels of NT-proBNP in response to breathing severely
hypoxic gas mixture in healthy young male volunteers to
study the possibility that hypoxia per se could trigger the
release of NT-proBNP. We did not find any consistent
increase in circulating NT-proBNP, which was likely due
to the fact that despite the marked reduction of oxygen
saturation, oxygen supply to the cardiomyocytes was
fully compensated for by the increased coronary blood
flow in these healthy young adults. Nevertheless, two
distinct NT-proBNP response groups to hypoxia were
also identified in the present study. It will be discussed
that this divergent response is likely related to hypoxic
regulation of BNP genetic responses, and in the long
term might determine individual adaptation to chronic
hypoxia.Our findings in terms of cardiac responses to acute sys-
temic hypoxia are well in accordance with the established
literature, which also describes tachycardia and largely un-
changed blood pressure as one of the key feature of hypoxic
physiological response [16-18]. Although hypoxia sup-
presses myocardial contractility in some studies that have
been performed in vitro, also our finding of higher ejection
fraction, thus improved emptying of the ventricle, supports
the notions that hypoxia may induce compensatory im-
provement in cardiac pump function in vivo in healthy
humans [16,19]. Moreover, although a decrease in early-to-
late filling (E/A-ratio) of the ventricle was also observed in
the present study, which would normally suggest impaired
diastolic filling, it has been previously documented that this
is largely the result of decreased early filling due to preload
reduction, while there is simultaneously a greater contribu-
tion of atrial contraction in acute systemic hypoxia [16].
However, when it comes to the NT-proBNP levels during
acute hypoxic exposure, as sampled repeatedly during the
exposure, as well as the 2 and 24 h level after hypoxic ex-
posure, we observed that it remained essentially similar to
the pre-exposure baseline NT-proBNP level. This was the
case even when the arterial oxygen saturation dropped
close to 70% during the severe acute hypoxic exposure.
However, despite this reduction it is likely that absolute
oxygen supply to heart was not actually decreased, as cor-
onary blood flow velocity increased by 75% while the diam-
eter of left anterior coronary artery remained unchanged.
Therefore, it is apparent that the investigation of BNP re-
lease is hampered by the fact that despite the reduction of
oxygen saturation, oxygen supply of the cardiomyocytes is
mostly fully compensated by the increased coronary blood
flow in healthy young adults.
From the present results it is clear that breathing severely
hypoxic gas mixture does not elicit increased NT-proBNP
level, as despite the decreased arterial oxygen saturation
cardiac myocytes can obtain unchanged (or even increased)
amount of oxygen as myocardial blood flow increases
markedly [20]. Myocardial hypoxia may however occur if
coronary blood flow cannot respond to reduced oxygen sat-
uration or oxygen demand is excessively increased, as might
happen in many cardiac patients in which BNP is fre-
quently determined as a diagnostic measure. Local cardiac
hypoxia typical for many cardiac patients may cause the in-
crease in circulating NT-proBNP levels, in addition to well-
established causes of pressure and volume overload [21-23],
but unfortunately, ischemia-prone individuals were not in-
vestigated in the present study and this aspect warrants fur-
ther experimentation. Another possible explanation in
addition to the blood flow compensation is that our one-
hour hypoxic exposure was too short to induce the expres-
sion of BNP gene. In long-term experiments circulating
BNP has been shown to be increased especially in subjects
who suffer from chronic mountain sickness [24-26], but
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remains open, as these studies are also confounded by sev-
eral other stress factors, such as physical stress caused by
hiking to and on the mountains and not be hypoxia per se.
These findings have neither been confirmed by all studies
[27]. Preoperative BNP levels are also within normal levels
in patients with tetralogy of Fallot (severe congenital cyan-
otic heart defect) who have generally at least moderate de-
creases in systemic oxygen saturation [28].
Finally, despite the fact that no increase in mean levels of
NT-proBNP was detected in the present study, we observed
two differently responding groups; in five subjects, the 24 h
concentration of NT-proBNP was higher than the baseline
concentration, while in five subjects it was lower. As these
divergent responses could not be related to changes in car-
diac function during hypoxia, it is possible that these differ-
ing responses are due to differences in single nucleotide
polymorphisms in gene areas regulating BNP expression. In
this regard it is interesting that BNP gene is under the direct
control of HIF (hypoxia-inducible factor) [5,7,29], which is
the master regulator of hypoxic responses. Thus, it remainsto be investigated whether these two divergent BNP re-
sponses could be localized to differences in single nucleotide
polymorphisms that are under the control of HIF.
Moreover, it might also be that these differences in NT-
BNP responses also determine the susceptibility to hypoxic
mountain sickness [24-26]. In this regard, circulating BNP
has been shown by Ge and Mo et al. to be predictive of
chronic mountain sickness [26]. However, in their study pa-
tients with mountain sickness also had higher pulmonary
artery pressures and lower arterial oxygen saturations com-
pared to subjects who did not get altitude sickness [26].
Therefore, it might be that also in this case the increase in
BNP is just a result of increased cardiac pressures [21-23],
but further studies are still warranted to investigate the
emerging evidence from animal studies that hypoxia, and/
or ischemia, per se could trigger the release of brain natri-
uretic peptides also in humans.
Methodological considerations
It is a limitation that we did not measure NT-proBNP levels
directly from coronary sinus, but instead peripheral venous
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ceptors, this may have caused NT-proBNP to be diluted to
body fluids and lowered the detection limit to observe
changes. However, not even a trend towards changes was
observed as whole study group level, although on the other
hand changes were robust when investigated at the sub-
group level indicating the validity of peripheral sampling.
Moreover, circulating levels of BNP show a close relation-
ship with its content in myocardium [30], making its meas-
urement from peripheral blood valid approach, especially in
healthy volunteers who have no medical or other reasons
for cardiac catheterization.
In conclusion, we did not find increase in circulat-
ing NT-BNP in response to breathing severely hyp-
oxic gas mixture in humans in the present study.
However, cardiac myocytes did not probably experi-
ence reduced amount of oxygen, as despite the fact
that arterial oxygen saturation was markedly reduced,
oxygen supply to the cardiomyocytes was likely fully
compensated for by the increased coronary blood flow
in the studied healthy young adults. Acute studies pa-
tients with cardiac diseases, especially those with lim-
ited possibility to adjust coronary blood flow, and
chronic hypoxic exposure studies in healthy humans
under well-controlled conditions are required to con-
clusively show the role of hypoxia in triggering NT-
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